GeoVax to Discuss BARDA Contract Termination at Emerging Growth Conference
TL;DR
GeoVax Labs, Inc. to discuss GEO-CM04S1 program and BARDA contract termination, providing valuable insights for investors.
GeoVax Labs, Inc. will present at Emerging Growth Conference on April 16, 2025, focusing on GEO-CM04S1 program and BARDA contract termination details.
GeoVax Labs, Inc.'s research on immunotherapies and vaccines aims to combat infectious diseases and improve cancer treatments, promising a brighter future for healthcare.
Join the live online event to interact with GeoVax Labs, Inc.'s Chairman and CEO, David Dodd, and stay updated on groundbreaking developments in biotechnology.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotechnology company GeoVax Labs is set to offer shareholders and investors a comprehensive update on its COVID-19 vaccine development program during the upcoming Emerging Growth Conference. CEO David Dodd will deliver a presentation focusing on the recent termination of the company's contract with the Biomedical Advanced Research and Development Authority (BARDA).
The conference, scheduled for April 16-17, 2025, will provide a live, interactive platform for investors to gain direct insights into the company's current research trajectory and strategic priorities. Dodd's presentation, set for 3:40 pm ET on April 16, will specifically address the implications of the BARDA contract termination for the company's lead clinical program, GEO-CM04S1.
GeoVax's GEO-CM04S1 vaccine is currently being evaluated across three distinct Phase 2 clinical trials. These trials represent critical research targeting specific patient populations, including immunocompromised individuals, patients with chronic lymphocytic leukemia, and those seeking more robust booster protection after initial mRNA vaccination.
The contract termination raises important questions about the future development and potential commercialization of the vaccine. Investors and industry observers will likely be keen to understand how GeoVax plans to proceed with its COVID-19 vaccine research and development in the absence of BARDA funding.
Beyond its COVID-19 program, GeoVax continues to advance multiple research initiatives. The company is simultaneously developing an oncolytic solid tumor gene-directed therapy called Gedeptin® and a vaccine targeting Mpox and smallpox, demonstrating its commitment to diversified medical research.
The Emerging Growth Conference represents a critical opportunity for GeoVax to transparently communicate its current scientific and strategic position to stakeholders. By providing a platform for direct interaction, the conference allows the company to address potential concerns and articulate its vision for future research and development efforts.
Interested parties can attend the conference live or access an archived webcast following the event, ensuring broad accessibility to the company's updates and insights.
Curated from NewMediaWire
